Relevant bibliographies by topics / Long-acting injectable antipsychotics

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Long-acting injectable antipsychotics'

Author: Grafiati
Published: 4 June 2021
Last updated: 2 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Long-acting injectable antipsychotics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Long-acting injectable antipsychotics"

1

Johnston, Karen, Jennifer Kern Sliwa, Cynthia A. Bossie, Edward Kim, and Barbara J. Limandri. "Long-Acting Injectable Antipsychotics." Journal of Psychosocial Nursing and Mental Health Services 57, no. 11 (2019): 5. http://dx.doi.org/10.3928/02793695-20191016-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Correll, Christoph U., and John Lauriello. "Long-Acting Injectable Antipsychotics." Journal of Clinical Psychiatry 79, no. 1 (2018): AL17017WC1C. http://dx.doi.org/10.4088/jcp.al17017wc1c.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Aparasu, Rajender R., and Sanika Rege. "Long-Acting Injectable Antipsychotic Medications in Schizophrenia Management." International Journal of Pharmaceutical Sciences and Nanotechnology 10, no. 6 (2016): 3507–11. http://dx.doi.org/10.37285/ijpsn.2017.10.6.2.

Full text
Abstract:
Antipsychotic medications are indicated for the treatment of schizophrenia and other psychiatric disorders including bipolar disorder. However, oral antipsychotics are associated with a number of issues including poor treatment adherence. Long Acting Injectable (LAI) antipsychotics were designed to address these issues with oral antipsychotics. LAI antipsychotics offer several advantages including less frequent dose administration, better adherence and tolerability, and relapse prevention, which in turn help in improving patients’ quality of life. Recent development of atypical antipsychotics
APA, Harvard, Vancouver, ISO, and other styles
4

Olagunju, Andrew T., Scott R. Clark, and Bernhard T. Baune. "Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome." Australian & New Zealand Journal of Psychiatry 53, no. 6 (2019): 509–27. http://dx.doi.org/10.1177/0004867419837358.

Full text
Abstract:
Objective: Impairment in psychosocial function is common in schizophrenia. Long-acting injectable atypical antipsychotics are thought to enhance psychosocial function by boosting adherence. However, no systematic review has examined the effects of long-acting injectable atypical antipsychotics on psychosocial function in clinical trials. Methods: We searched major databases including Medline/PubMed, PsychINFO, EMBASE, CINAHL, Scopus, Web of Science, Cochrane Central Register of Controlled Trials and Clinical Trial Registries for randomised controlled trials that compared long-acting injectable
APA, Harvard, Vancouver, ISO, and other styles
5

Gómez, L. Pérez, A. Gónzalez Fernández, D. F. Frías Ortíz, et al. "Long-acting injectable antipsychotics: Diagnostics and patient profile." European Psychiatry 33, S1 (2016): S616. http://dx.doi.org/10.1016/j.eurpsy.2016.01.2305.

Full text
Abstract:
IntroductionLong-acting injectable antipsychotics (LAIs) were developed in the sixties with the purpose of improving schizophrenia maintenance treatment. The main advantages are: the ability to ensure compliance, maintaining stable plasma concentrations and allowing better clinical management of drug therapy. Long-acting atypical injectable antipsychotics start to develop in the late nineties. Currently, they are the most widely used depot treatment for severe mental illness.ObjectiveChecking patient profile and diagnosis where we use LAIs.MethodsReview of 217 patients treated with LAIs in CSM
APA, Harvard, Vancouver, ISO, and other styles
6

Citrome, Leslie. "Long-acting injectable antipsychotics: what, when, and how." CNS Spectrums 26, no. 2 (2021): 118–29. http://dx.doi.org/10.1017/s1092852921000249.

Full text
Abstract:
AbstractCurrent guidelines for the treatment of patients with schizophrenia advocate that patients receive treatment with a long-acting injectable (LAI) antipsychotic medication if they prefer such treatment or if they have a history of poor or uncertain adherence. Available LAI formulations in the United States include first-generation antipsychotics (fluphenazine decanoate and haloperidol decanoate), risperidone/paliperidone containing products (risperidone microspheres, paliperidone palmitate, and risperidone subcutaneous), aripiprazole containing products (aripiprazole monohydrate and arip
APA, Harvard, Vancouver, ISO, and other styles
7

Ustohal, Libor. "Long-acting injectable antipsychotics in clinical practice." Klinická farmakologie a farmacie 31, no. 3 (2017): 10–15. http://dx.doi.org/10.36290/far.2017.016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bosanac, Peter, and David Jonathan Castle. "Why are long-acting injectable antipsychotics still underused?" BJPsych Advances 21, no. 2 (2015): 98–105. http://dx.doi.org/10.1192/apt.bp.114.013565.

Full text
Abstract:
Summary‘Depot antipsychotics' (‘long-acting injectable antipsychotic medications' or LAIs) are underused in the treatment of schizophrenia (including first episodes) and, possibly, of schizophrenia with comorbid substance use disorders. Patients' and clinicians' beliefs and attitudes, and service barriers, affect best practice and evidence-based care in LAI prescription. Poor medication adherence is a key reason for LAI prescription, but patients receiving LAIs may still relapse or experience significant side-effects. Patients' and clinicians' attitudes towards antipsychotic medication, as wel
APA, Harvard, Vancouver, ISO, and other styles
9

Toja-Camba, Francisco José, Nerea Gesto-Antelo, Olalla Maroñas, et al. "Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics." Pharmaceutics 13, no. 7 (2021): 935. http://dx.doi.org/10.3390/pharmaceutics13070935.

Full text
Abstract:
Over the last two decades, pharmacogenetics and pharmacokinetics have been increasingly used in clinical practice in Psychiatry due to the high variability regarding response and side effects of antipsychotic drugs. Specifically, long-acting injectable (LAI) antipsychotics have different pharmacokinetic profile than oral formulations due to their sustained release characteristics. In addition, most of these drugs are metabolized by CYP2D6, whose interindividual genetic variability results in different metabolizer status and, consequently, into different plasma concentrations of the drugs. In t
APA, Harvard, Vancouver, ISO, and other styles
10

Masand, Prakash S., and Sanjay Gupta. "Long-Acting Injectable Antipsychotics in the Elderly." Drugs & Aging 20, no. 15 (2003): 1099–110. http://dx.doi.org/10.2165/00002512-200320150-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Long-acting injectable antipsychotics"

1

Charles, Bhaskaran Nathamaniar. "A retrospective observational study of the effectiveness of long acting antipsychotic injectable on hospital admissions." Master's thesis, University of Cape Town, 2018. http://hdl.handle.net/11427/29562.

Full text
Abstract:
Background: The impact on hospitalisations/ relapse rates of utilising long-acting antipsychotic injectable (LAIs) in a South African population suffering from chronic psychotic spectrum mental illness is poorly researched. Aim: To compare the duration and number of hospitalisation episodes 12 and 24 months before and after the initiation of a LAI. Setting: Valkenberg Hospital’s adult acute inpatient psychiatry services. Method: This was a retrospective naturalistic observational mirror-image study. Hospitalisation was utilised as a proxy for relapse. Results: Sixty-one patients were identifie
APA, Harvard, Vancouver, ISO, and other styles
2

Samalin, Ludovic. "Attitudes et croyances vis-à-vis du traitement comme variables intermédiaires du comportement d'usage du médicament." Thesis, Clermont-Ferrand 1, 2016. http://www.theses.fr/2016CLF1MM21/document.

Full text
Abstract:
La prise en charge des patients souffrant d’un trouble mental justifie une meilleure compréhension des mécanismes influençant les comportements des patients et des cliniciens vis-à-vis des stratégies thérapeutiques. Le principal objectif de cette thèse est d’étudier et d’identifier le rôle des attitudes des patients et des cliniciens vis-à-vis du comportement d’usage d’une thérapeutique. Pour cela, nous avons réalisé plusieurs études permettant d’appréhender cette problématique dans différentes pathologies et envers différentes thérapeutiques.Concernant les attitudes des patients envers leur t
APA, Harvard, Vancouver, ISO, and other styles
3

Medrano, Sophia. "Impact des antipsychotiques à action prolongée sur l’évolution des jeunes adultes présentant un premier épisode psychotique." Thèse, 2017. http://hdl.handle.net/1866/20506.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Long-acting injectable antipsychotics"

1

Ellison, Justin C., Jason B. Rosenstock, and Michael J. Marcsisin. Somatic Treatments for Psychotic Disorders. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199331505.003.0006.

Full text
Abstract:
A variety of somatic therapies can be used to treat individuals suffering from psychosis. Most commonly, providers will prescribe antipsychotics, which generally block dopamine receptors and are particularly useful at reducing positive symptoms. Second-generation antipsychotics have fewer movement side effects than older agents do, but they are more expensive and have more metabolic side effects. Long-acting injectable (LAI) antipsychotics can be useful for improving outcomes, especially in non-adherent patients, and clozapine is the gold standard for treatment-refractory psychosis. Other agen
APA, Harvard, Vancouver, ISO, and other styles
2

Tracy, Derek K., and Fiona Gaughran. Treatment with medication: Side effects, adherence, and risk. Edited by Alec Buchanan and Lisa Wootton. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198738664.003.0009.

Full text
Abstract:
Antipsychotic medications revolutionized the care of psychosis, but they have brought with them significant side effects and issues around adherence; these latter factors, and informed co-working with patients, are primary drivers for specific medication choices. The data remain limited for polypharmacy and above-maximum dose prescribing, though there may be individuals for whom this is considered. Long-acting injectables (LAIs or ‘depots’) have a good evidence base, and are probably underutilized, though clozapine remains our drug of choice in refractory illness. Forensic-population data show
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Long-acting injectable antipsychotics"

1

Freudenreich, Oliver. "Long-Acting Injectable Antipsychotics." In Psychotic Disorders. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-29450-2_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kishimoto, Taishiro, Christoph U. Correll, and John M. Kane. "Comparative effectiveness of oral antipsychotics and long-acting injectable antipsychotics." In Antipsychotic Long-acting Injections. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198729471.003.0004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Emsley, Robin, Bonga Chiliza, and Laila Asmal. "Long-acting injectable antipsychotics in early psychosis." In Antipsychotic Long-acting Injections. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198729471.003.0010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Emsley, Robin, Bonga Chiliza, Laila Asmal, and Mathias de Fleuriot. "Long-acting injectable antipsychotics in early psychosis*." In Antipsychotic long-acting injections. Oxford University Press, 2010. http://dx.doi.org/10.1093/med/9780199586042.003.0007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lambert, Tim. "The management of a specialist clinic for long-acting injectable antipsychotics." In Antipsychotic Long-acting Injections. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198729471.003.0014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tacchi, Mary Jane, Jennifer Nendick, and Jan Scott. "Patient choice and long-acting injectable medication." In Antipsychotic Long-acting Injections. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198729471.003.0012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tacchi, Mary Jane, Jennifer Nendick, and Jan Scott. "Patient choice and improving the uptake of long-acting injectable medication*." In Antipsychotic long-acting injections. Oxford University Press, 2010. http://dx.doi.org/10.1093/med/9780199586042.003.0009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Meltzer, Herbert Y., and William V. Bobo. "Antipsychotic and anticholinergic drugs." In New Oxford Textbook of Psychiatry, edited by John R. Geddes, Nancy C. Andreasen, and Guy M. Goodwin. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198713005.003.0064.

Full text
Abstract:
Antipsychotic drugs are utilized for far more than the treatment of psychosis in schizophrenia, their first indication. They now find wide use in a variety of psychotic disorders, mood disorders, developmental disorders, and drug-induced disorders. The classification of drugs as typical or atypical is based on their differences in extra-pyramidal side effects (EPS). This chapter emphasizes the greater diversity, efficacy, and safety of the atypical drugs, and the risk of tardive dyskinesia of the typical drugs. The atypical drug action may produce improvement in cognitive function and negative symptoms, as well as psychosis and mood in some patients. This diversity includes atypical drugs which produce minimal weight gain. Long-acting injectable formulations are recommended for non-adherent patients. The exceptional ability of clozapine to reduce the risk for suicide and to decrease mortality in schizophrenia is discussed. Anticholinergic and other drugs to treat EPS are also discussed.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Long-acting injectable antipsychotics"

1

Fernández Varela, AM, LM Martínez Agulleiro, B. Salazar Laya, D. Núñez Arias, and I. Rodríguez Penín. "4CPS-138 An observational retrospective study on treatment adherence of long acting injectable antipsychotics." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.239.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Castro Balado, A., E. Echarri-Arrieta, L. García-Quintanilla, et al. "4CPS-166 Analysis of the maintenance rate of long acting injectable antipsychotic treatment in outpatients." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.267.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Long-acting injectable antipsychotics' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography